Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention

NCT03732638 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03732638
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03732638 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention
Lead sponsor
Pfizer
Phase
Phase 2/3
Overall status
Completed
Start date
November 14, 2018
Completion date
February 2, 2021
Enrollment
1,590 (actual)
Sites
93

Conditions

As the registry lists them; a condition with its own page is linked.

migraine